Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT01755325 is registered in ClinicalTrials.gov with Junmin Li as lead sponsor.

NCT NCT01755325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01755325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Lead sponsor
Junmin Li
Phase
Phase 3
Overall status
Suspended
Start date
November 30, 2012
Completion date
December 31, 2018
Enrollment
680 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia